HCA Healthcare (HCA)
(Delayed Data from NYSE)
$415.54 USD
+9.06 (2.23%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $415.66 +0.12 (0.03%) 4:28 PM ET
2-Buy of 5 2
A Value B Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$415.54 USD
+9.06 (2.23%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $415.66 +0.12 (0.03%) 4:28 PM ET
2-Buy of 5 2
A Value B Growth D Momentum A VGM
Zacks News
Trump Budget 2021 Likely to Impact These Sector ETFs
by Sanghamitra Saha
President Donald Trump delivered his latest budget proposal for 2021 and out these ETFs in focus.
Virus Fears Dissipate and the Rally is Back On
by David Borun
The deadly Coronavirus continues to claims new victims in China, but doesn't appear to be interfering with expectations for global growth
HCA Healthcare (HCA) Q4 Earnings Beat Estimates, Rise Y/Y
by Zacks Equity Research
HCA Healthcare's (HCA) Q4 results gain traction from better revenues and increased admissions.
HCA Holdings (HCA) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
HCA (HCA) delivered earnings and revenue surprises of 0.98% and 1.58%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights: Chevron, Netflix, NextEra, IBM and HCA
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Chevron, Netflix, NextEra, IBM and HCA
What's in Store for HCA Healthcare's (HCA) Q4 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) Q4 results are likely to reflect healthy growth in revenues and admissions.
Dose of Bright Near-Term Outlook From Medical-Hospital Industry
by Sapna Bagaria
Investment in technology, an aging population and continuous consolidation offers attractive growth opportunity for the industry.
Q4 Earnings Scorecard and Research Reports on Netflix, Chevron & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Chevron (CVX), Netflix (NFLX) and NextEra Energy (NEE).
HCA Healthcare Acquires Valify to Rein in Medical Costs
by Zacks Equity Research
HCA Healthcare (HCA) completes the buyout of technology company Valify to identify opportunities for reducing expenses.
4 Sector ETFs & Stocks to Win Despite Soft December Jobs Data
by Sanghamitra Saha
December U.S. jobs report came in weaker than expected. Still, these sector ETFs and stocks appear to be better-placed.
Why Should You Hold HCA Healthcare in Your Portfolio Now?
by Zacks Equity Research
Riding high on its growing revenues and a firm capital position, HCA Healthcare (HCA) holds potential to reap benefits for investors.
HCA Healthcare Acquires Galen, Expands Nursing Schools
by Sapna Bagaria
The acquisition of a majority ownership of Galen College of Nursing provides HCA Healthcare (HCA) with consistent availability of nurses.
MEDNAX Expands Further in Florida With Radiology Affiliation
by Zacks Equity Research
MEDNAX (MD) forms an association with Boca Radiology Group to strengthen its radiology business in Florida.
Community Health Divests Hospitals to Reduce Debt Level
by Zacks Equity Research
Community Health (CYH) continues to divest hospitals to focus on core operations and reduce debt burden.
Should Value Investors Buy HCA Holdings (HCA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Will Select Medical's Solid Run in 2019 Sustain in 2020?
by Zacks Equity Research
Acquisitions, partnerships and growth in admissions to drive Select Medical's (SEM) performance in 2020.
Community Health Lags Industry YTD: Will it Reverse in 2020?
by Zacks Equity Research
Backed by lower expenses, debt repayment and business streamlining, Community Health (CYH) holds enough potential to grow in 2020.
Pick These 5 Stocks With Superb Interest Coverage Ratio
by Sumit Singh
Interest coverage ratio is used to determine how effectively a company can pay the interest charged on its debt.
MEDNAX (MD) Catches Eye: Stock Jumps 8.1%
by Zacks Equity Research
MEDNAX (MD) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
6 Trade-Proof Sector ETFs to Follow if No Deal is Cracked
by Sanghamitra Saha
These sector ETFs are almost trade-resistant and thus unlikely to suffer if no deal is cracked before Dec 15.
These 5 Stocks Sport Impressive Interest Coverage Ratio
by Sumit Singh
Interest Coverage Ratio is used to determine how effectively a company can pay the interest charges on its debt.
HCA (HCA) Up 3.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
HCA (HCA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why is HCA Healthcare an Attractive Stock for Your Portfolio?
by Zacks Equity Research
Growing revenues and a strong capital position bode well for HCA Healthcare (HCA).
HCA (HCA) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
HCA (HCA) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Healthcare Stocks in Focus on Price Transparency Rule
by Sapna Bagaria
Hospital stocks gain from a less-than-expected strict price transparency rule and health insurers' optimism on a likely rise in profitability from a low-cost plan.